MIST Hits A Milestone: FDA Approves First-Ever Self-Administered Nasal Spray For PSVT

Milestone Pharmaceuticals (MIST) won FDA approval for CARDAMYST, an intranasal, rapid-acting calcium‑channel blocker to convert acute symptomatic paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults—the company’s first commercial product and the first FDA‑approved PSVT therapy in more than 30 years. CARDAMYST, which enables patient self‑administration outside emergency settings and addresses a U.S. patient population of more than two million, is slated to reach retail pharmacies in Q1 2026, positioning Milestone to disrupt acute PSVT care pathways if uptake and reimbursement follow. Management will host a conference call on Dec. 15, 2025; the stock showed volatility recently—hitting a 52‑week intraday high of $3.06 on Dec. 12 but closing at $2.41 (down 18.3%)—reflecting market caution around commercialization execution and demand visibility.

Analysis

Milestone Pharmaceuticals (MIST) received FDA approval for CARDAMYST nasal spray to convert acute symptomatic paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is a novel rapid-acting intranasal calcium channel blocker and represents the first FDA-approved PSVT treatment in more than 30 years, addressing a U.S. patient population of over two million and enabling self-administration outside emergency settings.

Milestone expects retail pharmacy availability in Q1 2026 and will host a conference call on December 15, 2025 to discuss details; the announcement has produced marked share-price volatility, with the stock touching a 52-week intraday high of $3.06 on Dec. 12 before closing at $2.41 (down 18.31%). Sentiment metrics are moderately positive (sentiment ~0.55–0.6), indicating optimism about the clinical and convenience advantages but tempered by commercialization uncertainty.

Near-term fundamental catalysts and risks center on launch execution: pricing, payer coverage, distribution partnerships, manufacturing scale-up and early prescription uptake. Absent sales guidance in the release, revenue visibility is limited and the Dec. 15 call plus Q1 2026 pharmacy listings will be critical to re-rate the stock; failure to secure coverage or demonstrate initial demand would likely prolong downside pressure.

Key Decisions for Investors

• Monitor the Dec. 15 conference call for management's launch plan, pricing expectations, distribution partners and timing, and treat the call as the next key information catalyst
• Wait for tangible early commercial metrics—pharmacy listings, initial prescription volumes and payer coverage decisions in Q1 2026—before meaningfully increasing exposure given limited near-term revenue visibility
• If long, consider trimming or hedging near-term positions to protect against continued post-approval volatility reflected by the recent 18% one-day decline and execution risks
• Speculative investors may take a modest position to trade upside from successful outpatient uptake and favorable reimbursement, but size positions conservatively and set clear add/exit triggers tied to coverage and first-quarter sales data